NCT07329621TerminatedPhase 1
A Phase 1, Open-label, Positron Emission Tomography (PET) Trial to Measure Serotonin 5-HT2A Receptor Occupancy Following Single Oral Doses of MSP-2020 in Healthy Male Adults
Otsuka Pharmaceutical Development & Commercialization, Inc.2 sites in 1 country8 target enrollmentStarted: January 15, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 8
- Locations
- 2
- Primary Endpoint
- Percent Change in Specific Binding of [11C]CIMBI-36 from Baseline and EC50 Using Cortical Regions [11C]CIMBI-36 BPND
Study Overview
Brief Summary
This study is to see how well MSP-2020 attaches to specific targets in the brain called serotonin type 2A receptors (5-HT2AR). This study will also look at how much of the study drug (and its metabolite) is in the blood and how long the study drug stays in the blood, as well as the safety of MSP 2020.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 23 Years to 55 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Able to stay in the CRU for up to 4 days.
- •Body mass index (BMI) between 18.0 to 32.0 kg/m2 (inclusive).
- •In good health as determined by: a. Medical history; b. Physical and neurological examination; c. Concomitant medications; d. ECG; e. Screening echocardiogram; f. Serum chemistry, urinalysis, haematology, coagulation, and serology (HIV screen, HBsAg, and anti-HCV) tests.
Exclusion Criteria
- •In first-degree relatives, a history of any schizophrenia-spectrum disorder, psychotic disorder, or bipolar and related disorders.
- •History of allergy to tracer [11C]CIMBI-
- •MRI incompatibility due to implants including but not limited to pacemaker, artificial joints, or non-removable body piercings, and/or other contraindications for MRI such as claustrophobia, metal objects/fragments, or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals (eg, welding), or have motor problems that prevent the participant from lying still for the MRI.
- •Pathological MRI findings that would preclude from trial participation.
- •History of prior radiation exposure for research purposes such that participation in this trial would result in an ionising radiation exposure of > 10 mSv within a year (12 months) of the first PET scan that would cause the participant to exceed the yearly dose limit.
- •Have a negative modified Allen test at screening.
- •Contraindications to radial arterial cannula (including but not limited to cellulitis or other infections over the radial artery, absence of palpable radial artery pulse, or a clinically significant abnormal coagulation profile).
- •Clinically significant abnormality in past medical history, or at the screening physical examination, that in the investigator's or sponsor's opinion may place the participant at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of drug. This includes, but is not limited to, history of or concurrent cardiac, hepatic, renal, neurologic, endocrine, gastrointestinal, respiratory, haematologic, dermatologic, and immunologic disease.
- •History of alcohol and/or substance use disorder within the last 24 months according to the Diagnostic Statistical Manual of Mental Disorders and in past medical history or in the investigator's opinion, or intake of > 21 units of alcohol weekly, and the inability to refrain from alcohol use from 48 hours before screening and within 72 hours prior to dosing until discharge from the CRU on Day
- •One unit is equivalent to 1 (25 mL) measure of 40% spirits. For reference, one 330 mL bottle of 5% beer contains 1.7 units and a standard (175 mL) glass of 12% wine contains 2.1 units.
- •Note: Other protocol-specified Inclusion/Exclusion criteria may apply.
Arms & Interventions
MSP-2020 Oral Administration
Experimental
Participants will receive a single dose of MSP-2020 on Day 1.
Intervention: MSP-2020 (Drug)
Outcomes
Primary Outcomes
Percent Change in Specific Binding of [11C]CIMBI-36 from Baseline and EC50 Using Cortical Regions [11C]CIMBI-36 BPND
Time Frame: Up to Day 2
PK Plasma Concentration of MSP-2020 and its Metabolite
Time Frame: Up to Day 2
Maximum (peak) Plasma Concentration of MSP-2020 and its Metabolite
Time Frame: Up to Day 2
Time to Maximum (peak) Plasma Concentration of MSP-2020 and its Metabolite
Time Frame: Up to Day 2
Half-life (t1/2) of MSP-2020 and its metabolite
Time Frame: Up to Day 2
Area under the concentration-time curve (AUCt) of MSP-2020 and its metabolite
Time Frame: Up to Day 2
Secondary Outcomes
- Change from baseline in relevant scales(Up to Day 2)
- Change from Baseline in 5-Dimensional Altered States of Consciousness (5D-ASC) Score(Up to Day 2)
- Change from Baseline in 30-item Mystical Experience Questionnaire (MEQ-30) Score(Up to Day 2)
- Concentration of the metabolite at which 50% of the 5-HT2A receptors are occupied, as measured by PET imaging(Up to Day 2)
- Number of Participants With Adverse Events (AEs)(Up to Day 15)
- Change from Baseline in Subjective Drug Intensity Scale Score(Up to Day 2)
- Change from Baseline in Ego-Dissolution Inventory (EDI) Score(Up to Day 2)
- Number of Participants With Potentially Clinically Significant Changes in Vital Signs(Up to Day 2)
- Number of Participants With Potentially Clinically Significant Changes in Laboratory Tests(Up to Day 15)
- Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG)(Up to Day 2)
- Number of Participants With Potentially Clinically Significant Changes in Physical and Neurological Examinations(Up to Day 15)
- Number of Participants With Suicidality on Columbia-Suicide Severity Rating Scale (C-SSRS)(Up to Day 15)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
A PET study of serotonin transporter, activated microglia and energy metabolism measerment of the brain in Chronic Fatigue Syndrome.Chronic Fatigue SyndromeJPRN-UMIN000005469Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduated School of Medicine48
Completed
Not Applicable
Imaging serotonin transmission in the brain of depressed patients.Major depressive disorder, Adjustment disorder with depressionJPRN-UMIN000012050ational Institute of Radiological Sciences60
Active, not recruiting
Not Applicable
ongitudinal imaging of serotonin transporter occupancy using PET and [11C]DASB in patients with major depression treated with escitalopram or citalopram - PET with DASB comparing escitalopram to citalopramMajor depressionEUCTR2006-006576-38-ATSiegfried KASPER, O.Univ.Prof.Dr.Dr.h.c., Medizinische Universität Wien
Recruiting
Not Applicable
In vivo imaging of serotonin 1B receptor and synaptic density in autism spectrum disorder: a positron emission tomography study.Autism spectrum disorderJPRN-UMIN000042765Hamamatsu University School of Medicine60
Recruiting
Phase 1
A Positron Emission Tomography (PET) study to examine the properties of
a novel radioligand's suitability for imaging mutant huntingtin2024-515786-34-02CHDI Foundation Inc.27